Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
9 drugs in development
By Therapeutic Area
top 5
R&D Momentum
87/100
Pipeline Velocity
57/100
Trial Completion Rate
69/100
Pipeline Concentration
25/100
Pipeline Freshness
54/100
Strategic Signals
Activity
Last 14 days
California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis
A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
A Phase 2 Study of Olutasidenib in Combination With Azacitidine Followed by Olutasidenib Maintenance After Venetoclax Plus a Hypomethylating Agent Regimen (HMA-VEN) for IDH1-Mutated Acute Myeloid Leukemia (AML)
The Influence of Honey-flavored Yogurt on Low-grade Inflammation and Gut Health in Middle to Older Aged Women.
A Phase I Study to Evaluate the Safety of Escalating Doses of Lymphodepleting Conditioning Chemotherapy Prior to CD19 Chimeric Antigen Receptor T Cells in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)